Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ELDN with free AI briefings, catalyst countdowns, and dilution alerts.

ELDN · Eledon Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 10.0 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), a shelf registration filed May 1, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$69.7M Cash on Hand
10mo Cash Runway
Follow ELDN by email Get an email when ELDN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ELDN, unsubscribe in one click. Privacy

📣 What ELDN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tegoprubart Kidney Transplant Rejection Phase 3 · NCT07835581 Not yet recruiting
AT-1501 IV Infusion Brittle Type 1 Diabetes Mellitus Phase 1/2 · NCT05480657 Withdrawn
Islet transplantation with Tegoprubart… Type 1 Diabetes Mellitus Phase 1/2 · NCT06305286 Active not recruiting
Isolated cadaveric islet cells Brittle Type 1 Diabetes Mellitus Phase 1/2 · NCT05480657 Withdrawn
Siplizumab Kidney Failure Early Phase 1 · NCT06972069 Active not recruiting

Also used in these trials (approved or third-party drugs, not ELDN's own candidates): Tacrolimus Extended-Release.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ELDN holds $69.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $20.8M/quarter from operations, an estimated runway of 10 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELDN files for a raise →

👥 Who Owns ELDN

Insiders 10.6% Institutions (198 holders) 56.9% Public and other holders 32.5%
HolderTypeShares% of sharesAs of
BVF PARTNERS L P/IL
10% owner · +1.14M options
Insider 8,655,393 10.25% 2026-09-30
Matthew D. Perry Institution (13G, 5%+) 4,762,691 5.64% 2025-11-19
BlackRock, Inc. Institution (13G, 5%+) 4,380,857 5.19% 2026-03-31
David-Alexandre C Gros
Chief Executive Officer, Director · +1.68M options
Insider 168,663 0.20% 2026-07-31
Steven Perrin
President, Director · +1.11M options
Insider 81,215 0.10% 2026-07-31
Keith Katkin
Director · +77,175 options
Insider 8,575 0.01% 2026-01-10
Allan Kirk
Director · +30,870 options
Insider 3,430 0.00% 2026-01-10
Jan Hillson
Director · +30,870 options
Insider 3,430 0.00% 2026-01-10
James A. Jr. Robinson
Director · +30,870 options
Insider 3,430 0.00% 2026-01-10
June Lee
Director · +30,870 options
Insider 3,430 0.00% 2026-01-10
John S. McBride
Director · +30,870 options
Insider 3,430 0.00% 2026-01-10

Share count 84,459,713 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ELDN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELDN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.